michigan semaglutide gastric intestinal obstruction lawsuit glp-1 digestive blockage in Intolerance and Endoscopic Sleeve Options Ozempic Lawsuit: July 2026 Blindness – glp-1 gastrointestinal obstruction lawsuit in

Semaglutide belongs to a class of drugs known as glucagon-like peptide-1 receptor agonists

ERTU was reported to be noninferior to placebo with respect to the composite outcome of cardiovascular death, nonfatal MI, or nonfatal stroke [101]

Soon after Mounjaro went to market, there were reports of severe side effects, including gastroparesis and gastroenteritis

MET-097i vs Semaglutide: Ultra-Long-Acting vs Established GLP-1 Comparison Evidence-based comparison of MET-097i (ultra-long-acting once-monthly GLP-1 agonist) and semaglutide (established once-weekly/daily GLP-1 agonist) for weight loss and obesity treatment